FDA IRB Crackdown Garners Praise From Former Chief Counsel Hutt
This article was originally published in The Pink Sheet Daily
Executive Summary
Coast IRB investigation “shook up IRBs,” Hutt says during BIO panel, “which is good.” Former Deputy Commissioner Torti, Penn’s Fitzgerald note dangers of excessive regulation of IRBs.
You may also be interested in...
Enrollment Suspended In Trials Approved By Coast IRB After FDA Warning Letter
Many large and small drug firms are clients of Coast IRB, which was caught approving a fraudulent study.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.